Scientists in the field of epigenetics have found that the white matter of the central nervous system in a MS subject experience an upregulation in peptidylargininedeiminase-2 (PAD2) enzyme, which produces a less stable form of myelin basic protein and ultimately leads to the loss of immune tolerance [54]. Here, MBP is linked to myeloid sarcoma.